Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Purchased by Richard P Slaughter Associates Inc

Richard P Slaughter Associates Inc raised its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 1.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 149,406 shares of the biopharmaceutical company’s stock after buying an additional 2,770 shares during the quarter. Richard P Slaughter Associates Inc owned about 0.13% of Catalyst Pharmaceuticals worth $3,118,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of CPRX. TD Asset Management Inc acquired a new position in Catalyst Pharmaceuticals in the 2nd quarter valued at about $254,000. Arizona State Retirement System raised its holdings in shares of Catalyst Pharmaceuticals by 2.2% in the 2nd quarter. Arizona State Retirement System now owns 29,733 shares of the biopharmaceutical company’s stock valued at $461,000 after purchasing an additional 654 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its position in shares of Catalyst Pharmaceuticals by 3.5% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 79,630 shares of the biopharmaceutical company’s stock worth $1,233,000 after purchasing an additional 2,672 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Catalyst Pharmaceuticals by 9.6% during the second quarter. Dimensional Fund Advisors LP now owns 3,000,756 shares of the biopharmaceutical company’s stock worth $46,479,000 after purchasing an additional 263,099 shares in the last quarter. Finally, Renaissance Technologies LLC increased its holdings in Catalyst Pharmaceuticals by 15.2% in the second quarter. Renaissance Technologies LLC now owns 2,175,727 shares of the biopharmaceutical company’s stock valued at $33,702,000 after buying an additional 287,300 shares during the last quarter. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Price Performance

Shares of NASDAQ:CPRX opened at $22.19 on Wednesday. Catalyst Pharmaceuticals, Inc. has a 1-year low of $13.12 and a 1-year high of $24.27. The stock has a market cap of $2.65 billion, a P/E ratio of 18.81, a P/E/G ratio of 3.26 and a beta of 0.75. The firm has a fifty day moving average price of $21.78 and a 200 day moving average price of $20.11.

Insider Transactions at Catalyst Pharmaceuticals

In related news, insider Gary Ingenito sold 12,000 shares of the firm’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $22.72, for a total value of $272,640.00. Following the completion of the sale, the insider now owns 51,391 shares in the company, valued at $1,167,603.52. This trade represents a 18.93 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Molly Harper sold 17,500 shares of the stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $22.00, for a total value of $385,000.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 79,500 shares of company stock worth $1,754,140. Company insiders own 11.00% of the company’s stock.

Analyst Ratings Changes

A number of analysts have issued reports on the company. HC Wainwright lifted their price target on Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, January 10th. StockNews.com downgraded Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday. Bank of America reissued a “buy” rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. Stephens started coverage on shares of Catalyst Pharmaceuticals in a report on Monday, November 18th. They issued an “overweight” rating and a $35.00 target price for the company. Finally, Truist Financial increased their target price on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, November 11th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $32.86.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.